IFM Therapeutics ‘Lather, Rinse, Repeat’ Strategy On Track With $55M Financing
Executive Summary
The drug discovery company with a big pharma deal-making track record is launching a new subsidiary, IFM Quattro, and a drug discovery incubator, IFM Discovery. Scrip talked to IFM's new CEO Martin Seidel about what is ahead for the company.
You may also be interested in...
Novartis Goes All In On A Second Long-Term Bet With IFM
Deal Snapshot: Novartis partnered with IFM Due in 2019 and has now exercised an option to buy the IFM Therapeutics subsidiary, continuing its ongoing relationship with the group.
Novartis' Drug Discovery Head Jay Bradner On What NIBR Is Investing In
NIBR's Bradner talked to Scrip about how AveXis turbo-charged Novartis' gene therapy development, investing in inflammasome research, and partnering nimbly like a venture capitalist.
Novartis Dives Into Inflammasome Pool With IFM Tre Purchase
The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.